-

Hims & Hers Health, Inc. to Participate at Citi’s 2022 Virtual Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, announced today that co-Founder and Chief Executive Officer, Andrew Dudum, and Chief Financial Officer, Yemi Okupe, will participate in a fireside chat at Citi’s 2022 Virtual Health Conference, Thursday, February 24 at 3:30 pm Eastern time.

The fireside chat will be available for live streaming on the Hims & Hers investor relations website at https://investors.forhims.com/. The webcast will be archived and available for 12 months.

About Hims & Hers Health, Inc.

Hims & Hers is a multi-specialty telehealth platform transforming the way healthcare is delivered. Its digital platform enables access to treatments for a broad range of conditions, including those related to sexual health, hair loss, dermatology, mental health and primary care. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate. Prescriptions are fulfilled online through licensed pharmacies on a subscription basis, making accessing treatments simple, affordable, and straightforward. Through the Hims & Hers mobile app, consumers can access an ever-expanding range of educational programs, wellness content, community support, and other services that promote lifelong health and wellness. Hims & Hers products can also be found in tens of thousands of top retail locations in the United States. Launched in November 2017, Hims & Hers serves the entire United States and select locations in the United Kingdom. The company is publicly traded on the New York Stock Exchange. For more information about Hims & Hers, please visit forhims.com and forhers.com.

Contacts

Investor Relations
Jay Spitzer
+1 (415) 598-0718
Investors@forhims.com

Media Relations
Press@forhims.com

Hims & Hers Health, Inc.

NYSE:HIMS

Release Summary
Hims & Hers Health, Inc. to Participate at Citi’s 2022 Virtual Healthcare Conference
Release Versions

Contacts

Investor Relations
Jay Spitzer
+1 (415) 598-0718
Investors@forhims.com

Media Relations
Press@forhims.com

More News From Hims & Hers Health, Inc.

Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers Benefits, adding eight new partners to the Hims & Hers exclusive program. Joining founding partners Prenuvo and Eight Sleep are Natural Cycles, MyFitnessPal, Ladder, PVOLVE Studios, HelloFresh, Factor, Flo Health, Dexcom, and iFIT - a carefully curated lineup spanning nutrition, fitness, women's health, metabolic monitoring, an...

Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers’ first international generic GLP-1 offering, demonstrating the company’s ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at $149 CAD/month, making...

Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada

TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are available starting at $149/month CAD. GLP-1 treatments have transformed obesity and metabolic health, with...
Back to Newsroom